SCHEMBL3610263

SCHEMBL3610263

CCc1cccc2oc(COc3ccc(-c4ccc(S(=O)(=O)NC(C(=O)O)C(C)C)cc4)cc3)c(C)c12

nearest known ligand 0.76

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 18/20 0.76
MMP13 P45452 15/20 0.76
ADAMTS5 Q9UNA0 2/20 0.76
MMP2 P08253 4/20 0.70
MMP14 P50281 3/20 0.70
MMP3 P08254 1/20 0.70
MMP7 P09237 1/20 0.70
MMP8 P22894 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13314516 1.00 ADAMTS4 (0.76) ADAMTS4MMP13ADAMTS5MMP2MMP14
SCHEMBL5791629 0.93 MMP13 (0.66) ADAMTS4MMP13ADAMTS5MMP2MMP14
SCHEMBL3610423 0.92 ADAMTS4 (0.65) ADAMTS4MMP13ADAMTS5MMP2MMP14
SCHEMBL3611835 0.89 MMP13 (0.72) ADAMTS4MMP13ADAMTS5MMP2MMP14
SCHEMBL8285243 0.86 ADAMTS4 (1.00) ADAMTS4MMP13ADAMTS5MMP2MMP14
SCHEMBL1658611 0.86 ADAMTS4 (1.00) ADAMTS4MMP13ADAMTS5MMP2MMP14
SCHEMBL3619440 0.83 MMP13 (0.63) ADAMTS4MMP13ADAMTS5MMP2MMP14
SCHEMBL13314514 0.82 MMP13 (0.82) ADAMTS4MMP13ADAMTS5MMP2MMP14
SCHEMBL3616108 0.82 MMP13 (1.00) ADAMTS4MMP13ADAMTS5MMP2MMP14
SCHEMBL3611514 0.82 MMP13 (1.00) ADAMTS4MMP13ADAMTS5MMP2MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7420001-B2 Biaryl sulfonamides and methods for using same WYETH (US) 2008-09-02 US claimed
EP-1692124-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS Wyeth (US) 2006-08-23 EP claimed
WO-2005061477-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH (US) 2005-07-07 WO claimed
US-20050143422-A1 Biaryl sulfonamides and methods for using same WYETH (US) 2005-06-30 US claimed
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same WYETH (US) 2010-06-03 US disclosed
EP-1692124-B1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH CORP (US) 2008-10-15 EP disclosed
US-7420001-B2 Biaryl sulfonamides and methods for using same WYETH (US) 2008-09-02 US disclosed
EP-1692124-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS Wyeth (US) 2006-08-23 EP disclosed
WO-2005061477-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH (US) 2005-07-07 WO disclosed
US-20050143422-A1 Biaryl sulfonamides and methods for using same WYETH (US) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same STS, MMP3, AADAC ADAMTS4 113/4885MMP13 13/4885ADAMTS5 82/4885
US-20050143422-A1 Biaryl sulfonamides and methods for using same STS, MMP3, AADAC ADAMTS4 113/4885MMP13 13/4885ADAMTS5 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.